FDA Announces Priority Review For Merrimack's Pancreatic Cancer Drug
June 25, 2015 at 10:49 AM EDT
Shares of Merrimack are up 7% after announcing FDA priority review for MM-398, a pancreatic cancer drug.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.